Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus disease activity in a Phase 2 study 03 June
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease 03 June
RYBREVANT FASPRO pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited 31 May
